Tedisamil

Tedisamil
Clinical data
ATC code
Identifiers
  • 3,7-Bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H32N2
Molar mass288.479 g·mol−1
3D model (JSmol)
  • C1CC2([C@H]3CN(C[C@@H]2CN(C3)CC4CC4)CC5CC5)CC1
  • InChI=1S/C19H32N2/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16/h15-18H,1-14H2/t17-,18+ ☒N
  • Key:CTIRHWCPXYGDGF-HDICACEKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tedisamil (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III antiarrhythmic agent currently being investigated for the treatment of atrial fibrillation. Tedisamil blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of tedisamil have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria.[1] Tedisamil is administered intravenously and has a half-life of approximately 8 –13 hours in circulation.[1] Tedisamil is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents.[1] Tedisamil also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered.[2] Tedisamil is manufactured by Solvay Pharmaceuticals Inc. under the proposed trade name Pulzium.[3]

  1. ^ a b c Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P (July 2004). "Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter". Journal of the American College of Cardiology. 44 (1): 99–104. doi:10.1016/j.jacc.2004.03.047. PMID 15234416.
  2. ^ Fox KM, Henderson JR, Kaski JC, Sachse A, Kuester L, Wonnacott S (February 2000). "Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker". Heart. 83 (2): 167–71. doi:10.1136/heart.83.2.167. PMC 1729311. PMID 10648489.
  3. ^ Solvay Press Office. "Solvay Pharmaceuticals files Tedisamil, a new cardiometabolic product for the treatment of atrial fibrillation and atrial flutter". Retrieved February 1, 2011.